Akeso

This study is testing whether adding one or two new drugs (ivonescimab and AK117) to standard chemotherapy works better than chemotherapy alone for people with advanced pancreatic cancer that has spread. About 1,000 participants will be randomly assigned to receive either the new…

This early-stage study is testing a new drug called AK138D1 in people with advanced solid cancers that haven't responded to standard treatments. Researchers will give the drug to up to 200 participants to find the safest dose and see if it shows any signs of fighting their cancer…

This study is testing a combination of two investigational drugs, AK130 and AK112, for people with advanced pancreatic cancer that has worsened after up to two prior treatments. The main goals are to see if the drug combination is safe and if it can shrink tumors. The trial will …

This study is testing the safety and early effectiveness of a new two-drug combination (AK119 and AK112) for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the treatment can shrink tumors. I…

This study is testing a new combination of two immunotherapy drugs, called AK109 and AK104, for people with advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination, given with or without standard chemotherapy, can help control the cancer after…

This study is testing a new drug called AK112, given alone or in combination with other treatments, for people with advanced liver cancer. The first part checks safety and finds the right dose, while the second part compares AK112 treatments to current standard care. Researchers …

This study is testing a new combination of three drugs (AK104, AK112, and TT-00420) for people with advanced liver cancer that cannot be treated with surgery. The main goal is to see how well the combination shrinks tumors and controls the disease. It will involve about 100 parti…

This is the first study in people to test a new experimental cancer drug called AK146D1. The main goals are to find a safe dose and see how the body processes the drug in up to 200 adults with advanced solid tumors that have progressed after standard treatments. Researchers will …

This study is testing the safety and effectiveness of a new two-drug combination (AK130 + AK112) for people with advanced bile duct cancer that has worsened after initial treatment. The first part finds the safest dose, and the second part sees how well the drugs work together. I…

This large, late-stage study is testing whether adding an investigational drug called AK112 to standard chemotherapy works better than chemotherapy alone for people with advanced triple-negative breast cancer. It aims to see if the combination can better control the cancer and he…

This study is testing whether a new drug called AK112 can help keep small cell lung cancer from coming back in people who have just finished their initial chemo-radiation treatment. About 560 participants will be randomly assigned to receive either the real drug or a placebo (ina…

This large study is testing whether adding a new immunotherapy drug called cadonilimab to standard chemotherapy, given both before and after surgery, works better and is safe for people with operable stomach or gastroesophageal junction cancer. It aims to see if this combination …

This study is comparing two different drug combinations for people newly diagnosed with advanced colorectal cancer that has spread. It will test if a new drug called AK112, when added to standard chemotherapy, works better and is as safe as the current standard treatment of bevac…

This study is testing whether adding a new immunotherapy drug called cadonilimab to standard chemotherapy, given both before and after surgery, works better than chemotherapy alone for patients with a type of esophageal cancer that can be surgically removed. The goal is to see if…

This study is testing whether adding one of two experimental drugs to a new immunotherapy (ivonescimab) and standard chemotherapy works better for people newly diagnosed with extensive-stage small cell lung cancer. Researchers want to see which combination shrinks tumors most eff…